pharma · Achondroplasia · Amyloid Cardiomyopathy, Transthyretin-Related · BBOT
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics clinical programs — 0 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
256 E Grand Ave, Suite 104, South San Francisco, California 94080, US HQ
103 Employees
Public company Type
BBOT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 256 E Grand Ave, Suite 104, South San Francisco, California 94080, US
- Employees
- 103
- Programs
- 34
- Drugs
- 14
- Patents
- 1
BridgeBio Oncology Therapeutics projects
0 ClinicalTrials.gov programs sponsored by BridgeBio Oncology Therapeutics.
BridgeBio Oncology Therapeutics has 0 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
No programs matched
Frequently asked questions
How many clinical projects does BridgeBio Oncology Therapeutics have?
0 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.